Recently, EGFR/BRAF‐targeted therapy ± chemotherapy has been explored as the frontline approach for BRAF V600E mutant mCRC in ANCHOR‐CRC (NCT03693170) and the BREAKWATER trial (NCT01640405).25 The gene discussed is BRAF; the disease is colorectal carcinoma.